More Stories

Informist, Friday, Sept. 18, 2026

 

--Pharma secy: Regulatory process must move from serial to parallel execution

--CONTEXT: Pharma secy Manoj Joshi speaks at CII Pharma & Lifesciences Summit

--Pharma secy: Pharma industry needs to spend more on research, development

 

NEW DELHI – Indian pharmaceutical industry needs parallel execution of regulatory processes rather than serially, Manoj Joshi, secretary of the department of pharmaceuticals, said at the eighth CII Pharma & Life Sciences Summit here Friday. Currently, there is a lot of "distrust" between researchers and industry players. "We need to reduce that," Joshi said, as the industry requires a few sets of reforms to move ahead.

 

The secretary suggested that sector-specific regulators, researchers, and industry should focus on working together to streamline the regulatory process. He also urged the industry to increase spending on research and development. 

 

The regulators have been receiving a lot of pressure for reforms. In its wake, the secretary said that he was "quite hopeful that in the next one or two months, we would be making a lot of changes in our regulatory system". Joshi said India should make its regulatory system an advantage rather than a disadvantage and hoped that within a year, the country would also be cited as a place where the industry is able to move faster due to a swift regulatory system.

Pharmaceutical startups are taking more risk in terms of putting up manufacturing plants, contract development and manufacturing organisations, as well as investing more in research, Joshi said. However, it is otherwise for venture capitalists and other large companies as they are refraining from taking risks. "I see a lot of risk taken by a lot of startups. I do not see a lot of risk taken by a large number of pharma companies. I do not see a risk taken by a lot of venture funds or investment arms. I think that some part of the industry is really taking much of the risk and playing safer and safer," Joshi said.  End

 

Reported by Gunjan Rajput and Shweta

Edited by Shubhayan Bhattacharya

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.